Au Philip Cm, Lee Anne Wm, Lee Victor Hf, Wong Ian Ck, Hui Rina Ym, Cheung Ching-Lung
Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, L02-56, 2/F, Laboratory Block, 21 Sassoon Road, Pokfulam, Hong Kong SAR, China.
Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Lancet Reg Health West Pac. 2024 Feb 16;45:101030. doi: 10.1016/j.lanwpc.2024.101030. eCollection 2024 Apr.
Over the past decades, significant progress in lung cancer management has been made. However, the trends in prevalence and survival of lung cancer in the Chinese population over the last decade remain unexplored. This study utilised a territory-wide electronic medical database in Hong Kong to provide the most up-to-date and comprehensive analysis of the trends in prevalence, incidence, and survival over the past two decades.
Descriptive epidemiology study using a retrospective cohort of lung cancer patients from the Clinical Data Analysis and Reporting System (CDARS). 10-year limited-duration prevalence, incidence, and relative period survival were calculated between 2002 and 2021. Sub-groups of age, sex, and comorbidity were examined. The annual percent change (APC) and average annual percent change (AAPC) were estimated using joinpoint regression.
This study included 87,259 incident cases between 2002 and 2021. The 10-year limited duration prevalence (per 100,000 persons) of lung cancer increased from 153.4 to 228.7 (AAPC: 3.08%). Crude incidence (per 100,000 persons) increased from 55.0 to 70.3 (APC: 1.23%), while age-standardised incidence decreased from 42.9 to 33.2 (APC: -1.32%). The 1-year and 5-year relative period survivals showed an increasing trend but remained low. Disparity in trends was observed among different sex and age groups.
Lung cancer burden has been increasing partly due to population ageing. Although survival showed improvement over the years, it remained low, highlighting the potential need for interventions. Further study exploring the disparity in sex-specific trends is warranted.
The Innovation and Technology Commission, Hong Kong.
在过去几十年中，肺癌管理取得了重大进展。然而，过去十年中国人群肺癌的患病率和生存率趋势仍未得到探索。本研究利用香港全地区的电子医疗数据库，对过去二十年的患病率、发病率和生存率趋势进行了最新、最全面的分析。
采用描述性流行病学研究，对来自临床数据分析与报告系统（CDARS）的肺癌患者进行回顾性队列研究。计算了2002年至2021年期间的10年有限期患病率、发病率和相对期间生存率。对年龄、性别和合并症亚组进行了检查。使用Joinpoint回归估计年度百分比变化（APC）和平均年度百分比变化（AAPC）。
本研究纳入了2002年至2021年期间的87259例新发病例。肺癌的10年有限期患病率（每10万人）从153.4上升至228.7（AAPC：3.08%）。粗发病率（每10万人）从55.0上升至70.3（APC：1.23%），而年龄标准化发病率从42.9降至33.2（APC：-1.32%）。1年和5年相对期间生存率呈上升趋势，但仍然较低。不同性别和年龄组之间观察到趋势差异。
肺癌负担一直在增加，部分原因是人口老龄化。尽管多年来生存率有所提高，但仍然较低，这突出了潜在的干预需求。有必要进一步研究探索性别特异性趋势的差异。
香港创新及科技局。
